Separately, CBC also announced the launch of a new Asia-Pacific healthcare platform, in which it will invest alongside APG. Graeme Torre, the head of Asia-Pacific real estate for APG Asset Management, said “the advancement of healthcare and the development of the life sciences sector is a key objective” for China. Pharmaceutical breakthroughs that are needed today more than ever.” “It is critical that scientists and researchers are provided with world-class facilities to explore potential biotech and Hans Kang, CEO of CBC health care real estate, said: “We are excited to become the first mover in this space in China which is the most in-demand life science market globally and represents a multi-billion-dollar market opportunity. It aims to further develop its portfolio in key life science clusters in the top nine cities in China: Shanghai, Beijing, Guangzhou, Shenzhen, Suzhou, Hangzhou, Nanjing, Wuhan and Chengdu. The €610bn Dutch pension giant is providing $400m (€346m) seed capital for CBC’s China Life Science Infrastructure Venture (CLSIV), with CBC contributing $100m to the venture.ĬLSIV has a hard cap of $1.5bn of total equity commitments and will be dedicated to investing “in best-in-class facilities for life science research, manufacturing and support services catering to biotechnology incubators through to large multinational pharmaceutical companies in China”, according to a joint press release from APG and CBC.ĬLSIV has already made its first investment, securing nearly one million square metres of land to develop life science facilities in Shanghai. SPRAVATO™ can only be administered at healthcare settings certified in the SPRAVATO™ REMS Program and to patients enrolled in the program.įor more information on SPRAVATO™, please refer to the manufacturer’s Prescribing Information and Medication Guide or visit If you are a patient, please speak to your healthcare provider for more information.APG has made its first investment in Chinese life science real estate via a partnership with CBC Group, Asia’s largest healthcare-dedicated investment firm. SPRAVATO™ must never be dispensed directly to a patient for home use.Īdditionally, all patients will require transportation from APG Healthcare following the observation period,as they should not drive or operate machinery until the day after a treatment session, following a restful sleep.įor more information regarding administration, REMS requirements, or other related questions, please contact one of our administrative assistants at 40.īecause of the risks for sedation, dissociation(feeling disconnected from yourself, your thoughts, feelings, space and time),and abuse and misuse, SPRAVATO™ carries a Boxed WARNING and is only available through a restricted program called the SPRAVATO™ Risk Evaluation and Mitigation Strategy (REMS) Program. A healthcare provider will provide direct supervision as the patient self-administers SPRAVATO™ and will monitor every patient after every dose for at least two hours for resolution of sedation and dissociation and changes in vital signs. 2Īs a certified treatment center, our medical staff have been trained to prescribe, dispense and administer SPRAVATO™and have established processes and procedures in accordance with the REMS. 1 People who are currently struggling with major depressive disorder (MDD) may have TRD if they have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode. We are now Risk Evaluation and Mitigation Strategy (REMS) certified to provide SPRAVATO™ (esketamine) CIII, a nasal spray approved for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |